Suven Life Sciences Reports Negative Financial Results, MarketsMOJO Issues 'Sell' Call

Suven Life Sciences, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ended December 2023. According to the data released on January 30, 2024, the company has seen a negative performance in this quarter.

The company's score has fallen from -3 to -10 in the last three months, indicating a decline in its financial health. The Profit Before Tax (PBT) has also decreased by 35.1% to Rs -47.83 crore, compared to the average PBT of the previous four quarters which was Rs -35.39 crore. This shows a negative trend in the near term for PBT.

Similarly, the Profit After Tax (PAT) has also fallen by 44.6% to Rs -41.76 crore, compared to the average PAT of the previous four quarters which was Rs -28.88 crore. This indicates a negative trend in the near term for PAT.

In terms of sales, the company has reported a growth of -25.44% Year on Year (YoY) with net sales of Rs 5.51 crore in the first half of the financial year. However, the near term sales trend is negative.

The company's non-operating income has also increased in this quarter, with the highest amount of Rs 6.07 crore in the last five quarters. However, this increase may not be sustainable as it is from non-business activities.

Based on these financial results, MarketsMOJO has given a 'Sell' call for Suven Life Sciences' stock. Investors should take note of the negative trends and make informed decisions.